Objective: To investigate the mechanism of cell cyclin-dependent kinase (KDM5B), a
key enzyme driving all cell cycle transitions, promoting HCC progression and
metastasis.Methods: The expression of KDM5B in normal liver, HCC and its adjacent tissues
was analyzed by RT-PCR and IHC. Lentivirus transfection method was used to
construct stable cell lines with KDM5B overexpression and down-regulation, and
the role of KDM5B in HCC migration and invasion was detected at cell level and
animal level. Western blotting and Transwell experiments were performed to
verify the effect of KDM5B and/or CCR2 inhibitors on HCC progression and
metastasis by using liver orthotopic transplantation tumor model and
immunofluorescence methods.Results: RT-PCR showed that the expression level of KDM5B in HCC was
significantly higher than that in adjacent tissues, and the increase of KDM5B
was relatively significant. Upregulation of KDM5B in nude mouse liver
orthotopic transplantation tumor model can promote the incidence of lung
metastasis and shorten the survival time of nude mice, whereas upregulation of
KDM5B can reduce the incidence of lung metastasis and prolong the survival time
of nude mice.Conclusion: This study clarified the expression of KDM5B in HCC and its function in
promoting HCC migration, invasion and metastasis. The molecular mechanism of
KDM5B promoting HCC metastasis was revealed, providing a potential therapeutic
target for HCC.
References
[1]
Llovet, J.M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M. and Gores, G. (2016) Hepatocellular Carcinoma. Nature Reviews Disease Primers, 2, Article No. 16018. https://doi.org/10.1038/nrdp.2016.18
[2]
Forner, A., Reig, M. and Bruix, J. (2018) Hepatocellular Carcinoma. Lancet, 391, 1301-1314. https://doi.org/10.1016/S0140-6736(18)30010-2
[3]
Yang, J.D., Hainaut, P., Gores, G.J., Amadou, A., Plymoth, A. and Roberts, L.R. (2019) A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nature Reviews Gastroenterology & Hepatology, 16, 589-604.
https://doi.org/10.1038/s41575-019-0186-y
[4]
Zhu, A.X., Duda, D.G., Sahani, D.V., Jain, R.K. (2011) HCC and Angiogenesis: Possible Targets and Future Directions. Nature Reviews Clinical Oncology, 8, 292-301.
https://doi.org/10.1038/nrclinonc.2011.30
[5]
Villanueva, A. (2019) Hepatocellular Carcinoma. The New England Journal of Medicine, 380, 1450-1462. https://doi.org/10.1056/NEJMra1713263
[6]
Yang, W.X., Pan, Y.Y. and You, C.G. (2019) CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 May Be Potential Therapeutic Targets for Hepatocellular Carcinoma Using Integrated Bioinformatic Analysis. BioMed Research International, 2019, Article ID: 1245072. https://doi.org/10.1155/2019/1245072
[7]
Giordano, S and Columbano, A. (2014) Met as a Therapeutic Target in HCC: Facts and Hopes. Journal of Hepatology, 60, 442-452.
https://doi.org/10.1016/j.jhep.2013.09.009
[8]
Llovet, J.M., Montal, R., Sia, D. and Finn, R.S. (2018) Molecular Therapies and Precision Medicine for Hepatocellular Carcinoma. Nature Reviews Clinical Oncology, 15, 599-616. https://doi.org/10.1038/s41571-018-0073-4
[9]
Wang, D., Han, S., Peng, R., Jiao, C., Wang, X., Yang, X., Yang, R. and Li, X. (2016) Depletion of Histone Demethylase KDM5B Inhibits Cell Proliferation of Hepatocellular Carcinoma by Regulation of Cell Cycle Checkpoint Proteins p15 and p27. Journal of Experimental & Clinical Cancer Research, 35, Article No. 37.
https://doi.org/10.1186/s13046-016-0311-5
[10]
Bamodu, O.A., Huang, W.C., Lee, W.H., Wu, A., Wang, L.S., Hsiao, M., Yeh, C.T. and Chao, T.Y. (2016) Aberrant KDM5B Expression Promotes Aggressive Breast Cancer through MALAT1 Overexpression and Downregulation of hsa-miR-448, BMC Cancer, 16, Article No. 160. https://doi.org/10.1186/s12885-016-2108-5
[11]
Gong, J., Yan, S., Yu, H., Zhang, W. and Zhang, D. (2018) Increased Expression of Lysine-Specific Demethylase 5B (KDM5B) Promotes Tumor Cell Growth in Hep3B Cells and is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma. Medical Science Monitor, 24, 7586-7594.
https://doi.org/10.12659/MSM.910844
[12]
Guo, J.C., Yang, Y.J., Zhang, J.Q., Guo, M., Xiang, L., Yu, S.F., Ping, H. and Zhuo, L. (2019) microRNA-448 Inhibits Stemness Maintenance and Self-Renewal of Hepatocellular Carcinoma Stem Cells through the MAGEA6-Mediated AMPK Signaling Pathway. Journal of Cellular Physiology, 234, 23461-23474.
https://doi.org/10.1002/jcp.28915
[13]
Pu, Y., Xiang, J. and Zhang, J. (2020) KDM5B-Mediated microRNA-448 Up-Regulation Restrains Papillary Thyroid Cancer Cell Progression and Slows Down Tumor Growth via TGIF1 Repression. Life Sciences, 250, 117519.
https://doi.org/10.1016/j.lfs.2020.117519
[14]
Liu, J., Eckert, M.A., Harada, B.T., Liu, S.M., Lu, Z., Yu, K., Tienda, S.M., Chryplewicz, A., Zhu, A.C., Yang, Y., Huang, J.T., Chen, S.M., Xu, Z.G., Leng, X.H., Yu, X.C., Cao, J., Zhang, Z., Liu, J., Lengyel, E. and He, C. (2018) m(6)A mRNA Methylation Regulates AKT Activity to Promote the Proliferation and Tumorigenicity of Endometrial Cancer. Nature Cell Biology, 20, 1074-1083.
https://doi.org/10.1038/s41556-018-0174-4
[15]
Zhou, Y., Yin, Z., Hou, B., Yu, M., Chen, R., Jin, H. and Jian, Z. (2019) Expression Profiles and Prognostic Significance of RNA N6-Methyladenosine-Related Genes in Patients with Hepatocellular Carcinoma: Evidence from Independent Datasets. Cancer Management and Research, 11, 3921-3931.
https://doi.org/10.2147/CMAR.S191565
